Clinical Trial Update: Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial evaluating ORKA-002 in adults with moderate-to-severe plaque psoriasis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ORKA-002

Snippet

Sponsor: Oruka Therapeutics, Inc. | Conditions: Plaque Psoriasis | Phase 2 | Status: RECRUITING